Mcsp torfp no. NIH-ninds-20-02: mouradian/disney - base EC (parkinson's)
Ended Awarded Last action
- Contract number
- 75N95020F00002
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,392,674
Award facts
- Opportunity
-
- NIHNINDS2002 Solicitation number
- Contract value 34% obligated
-
- $1,392,674.46 Current, with exercised options
- $4,042,434.33 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $486,583 | |
| Change Order | $337,347 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $568,745 |
About this award
This is a delivery order contract awarded by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as Amri, for the Medicinal Chemistry Support Program for Therapeutic Development. The contract, with a potential value of $4,042,434.33, provides chemistry, manufacturing, and controls development; exploratory chemistry; hit-to-lead chemistry; absorption/distribution/metabolism/excretion testing; process chemistry; scale-up synthesis; good manufacturing practices production; stability testing; and other pharmaceutical development support across therapeutic areas like neurology. The contract does not have a set-aside designation. Curia has extensive experience supporting federal agencies like NIH through similar prime and subcontract awards, drawing on its capabilities as a leading global contract development and manufacturing organization.
Quick answers
Who was awarded contract 75N95020F00002?
75N95020F00002 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 1, 2020.
How much is contract 75N95020F00002 worth?
The government has obligated $1,392,674 on 75N95020F00002. Its potential value, with all options, is $4,042,434.
Which agency awarded contract 75N95020F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020F00002, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95020F00002 an order under another contract?
Yes. 75N95020F00002 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95020F00002 competed?
The extent of competition for 75N95020F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award